164 related articles for article (PubMed ID: 36975020)
1. A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022).
Kovalová M; Baraka JP; Mik V; Jorda R; Luo L; Shao H; Kryštof V
Expert Opin Ther Pat; 2023 Feb; 33(2):67-87. PubMed ID: 36975020
[TBL] [Abstract][Full Text] [Related]
2. Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy.
Liang H; Du J; Elhassan RM; Hou X; Fang H
Expert Opin Investig Drugs; 2021 Jan; 30(1):61-76. PubMed ID: 33183110
[No Abstract] [Full Text] [Related]
3. Cyclin-dependent kinase 7 inhibitors in cancer therapy.
Wang M; Wang T; Zhang X; Wu X; Jiang S
Future Med Chem; 2020 May; 12(9):813-833. PubMed ID: 32208930
[TBL] [Abstract][Full Text] [Related]
4. CDK7 inhibitors as anticancer drugs.
Sava GP; Fan H; Coombes RC; Buluwela L; Ali S
Cancer Metastasis Rev; 2020 Sep; 39(3):805-823. PubMed ID: 32385714
[TBL] [Abstract][Full Text] [Related]
5. Is Cdk7/cyclin H/MAT1 the genuine cdk activating kinase in cycling Xenopus egg extracts?
Fesquet D; Morin N; Doree M; Devault A
Oncogene; 1997 Sep; 15(11):1303-7. PubMed ID: 9315098
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal activation by cyclin-dependent kinases 2 and 7 is directed by substrate specificity determinants outside the T loop.
Garrett S; Barton WA; Knights R; Jin P; Morgan DO; Fisher RP
Mol Cell Biol; 2001 Jan; 21(1):88-99. PubMed ID: 11113184
[TBL] [Abstract][Full Text] [Related]
7. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.
Ali S; Heathcote DA; Kroll SH; Jogalekar AS; Scheiper B; Patel H; Brackow J; Siwicka A; Fuchter MJ; Periyasamy M; Tolhurst RS; Kanneganti SK; Snyder JP; Liotta DC; Aboagye EO; Barrett AG; Coombes RC
Cancer Res; 2009 Aug; 69(15):6208-15. PubMed ID: 19638587
[TBL] [Abstract][Full Text] [Related]
8. Characterization of new highly selective pyrazolo[4,3-d]pyrimidine inhibitor of CDK7.
Kovalová M; Havlíček L; Djukic S; Škerlová J; Peřina M; Pospíšil T; Řezníčková E; Řezáčová P; Jorda R; Kryštof V
Biomed Pharmacother; 2023 May; 161():114492. PubMed ID: 36931035
[TBL] [Abstract][Full Text] [Related]
9. Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study.
Hazel P; Kroll SH; Bondke A; Barbazanges M; Patel H; Fuchter MJ; Coombes RC; Ali S; Barrett AG; Freemont PS
ChemMedChem; 2017 Mar; 12(5):372-380. PubMed ID: 28125165
[TBL] [Abstract][Full Text] [Related]
10. Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7.
Hu S; Marineau JJ; Rajagopal N; Hamman KB; Choi YJ; Schmidt DR; Ke N; Johannessen L; Bradley MJ; Orlando DA; Alnemy SR; Ren Y; Ciblat S; Winter DK; Kabro A; Sprott KT; Hodgson JG; Fritz CC; Carulli JP; di Tomaso E; Olson ER
Cancer Res; 2019 Jul; 79(13):3479-3491. PubMed ID: 31064851
[TBL] [Abstract][Full Text] [Related]
11. p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner.
Ko LJ; Shieh SY; Chen X; Jayaraman L; Tamai K; Taya Y; Prives C; Pan ZQ
Mol Cell Biol; 1997 Dec; 17(12):7220-9. PubMed ID: 9372954
[TBL] [Abstract][Full Text] [Related]
12. MAT1 ('menage à trois') a new RING finger protein subunit stabilizing cyclin H-cdk7 complexes in starfish and Xenopus CAK.
Devault A; Martinez AM; Fesquet D; Labbé JC; Morin N; Tassan JP; Nigg EA; Cavadore JC; Dorée M
EMBO J; 1995 Oct; 14(20):5027-36. PubMed ID: 7588631
[TBL] [Abstract][Full Text] [Related]
13. Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery.
Fisher RP
Transcription; 2019 Apr; 10(2):47-56. PubMed ID: 30488763
[TBL] [Abstract][Full Text] [Related]
14. Dual phosphorylation of the T-loop in cdk7: its role in controlling cyclin H binding and CAK activity.
Martinez AM; Afshar M; Martin F; Cavadore JC; Labbé JC; Dorée M
EMBO J; 1997 Jan; 16(2):343-54. PubMed ID: 9029154
[TBL] [Abstract][Full Text] [Related]
15. CAK-Cyclin-dependent Activating Kinase: a key kinase in cell cycle control and a target for drugs?
Lolli G; Johnson LN
Cell Cycle; 2005 Apr; 4(4):572-7. PubMed ID: 15876871
[TBL] [Abstract][Full Text] [Related]
16. Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer.
Patel H; Abduljabbar R; Lai CF; Periyasamy M; Harrod A; Gemma C; Steel JH; Patel N; Busonero C; Jerjees D; Remenyi J; Smith S; Gomm JJ; Magnani L; Győrffy B; Jones LJ; Fuller-Pace F; Shousha S; Buluwela L; Rakha EA; Ellis IO; Coombes RC; Ali S
Clin Cancer Res; 2016 Dec; 22(23):5929-5938. PubMed ID: 27301701
[TBL] [Abstract][Full Text] [Related]
17. The cryoelectron microscopy structure of the human CDK-activating kinase.
Greber BJ; Perez-Bertoldi JM; Lim K; Iavarone AT; Toso DB; Nogales E
Proc Natl Acad Sci U S A; 2020 Sep; 117(37):22849-22857. PubMed ID: 32855301
[TBL] [Abstract][Full Text] [Related]
18. CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?
Diab S; Yu M; Wang S
J Med Chem; 2020 Jul; 63(14):7458-7474. PubMed ID: 32150405
[TBL] [Abstract][Full Text] [Related]
19. THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours.
Sun J; Zhang Q; Sun X; Xue A; Gao X; Shen K
Cell Commun Signal; 2022 Sep; 20(1):138. PubMed ID: 36076237
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Cak1p-like cyclin-dependent kinase-activating kinases.
Tsakraklides V; Solomon MJ
J Biol Chem; 2002 Sep; 277(36):33482-9. PubMed ID: 12084729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
